Efficacy and Safety Study of cediranib in combination with olaparib in Patients with Recurrent Platinum-Resistant Ovarian Cancer - CONCERTO

Study identifier:D8488C00001

ClinicalTrials.gov identifier:NCT02889900

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Medical condition

recurrent platinum resistant ovarian cancer

Phase

Phase 2

Healthy volunteers

Study drug

cediranib and olaparib

Sex

Female

Actual Enrollment

Study type

Interventional

Age

18 Years - 120 Years

Date

Study Start Date: 17 Jan 2017

Primary Completion Date: 27 Aug 2019

Study Completion Date: 16 Mar 2021

Study design

Allocation: N/A
Endpoint Classification: Safety/Efficacy
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Mar 2022 by AstraZeneca

Collaborators

Myriad Genetic Laboratories, Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc

Inclusion and exclusion criteria

Inclusion Criteria

1.Ability and willingness to provide written informed consent, and to comply with the requirements of the protocol
2.Females aged ≥18 years with previous histologically proven diagnosis of high grade serous, high grade endometroid or clear cell ovarian cancer, fallopian tube or primary peritoneal carcinoma
3.No evidence of deleterious or suspected deleterious germline mutation in BRCA1 or BRCA2 genes
4.Recurrent platinum-resistant disease, defined as disease progression within 6 months (182 days) of the last receipt of platinum-based chemotherapy
5.CT/MRI evidence of measurable disease as per RECIST 1.1 defined as at least one lesion, not previously irradiated, that can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes which must have short axis ≥ 15 mm) and which is suitable for accurate repeated measurements
6.Eastern Cooperative Oncology Group (ECOG) performance status 0-2
7.Life expectancy ≥12 weeks
8.Prior receipt of antiangiogenic treatment, including but not limited to bevacizumab, is optional. If used, it can be used in the first line or recurrent setting.
9.At least three prior lines of therapy for advanced ovarian cancer as defined in the protocol
10.Confirmation of the availability of a tumor sample from the primary or recurrent cancer must be provided
11.Patients must have adequate organ and bone marrow function
12.Adequately controlled blood pressure
13.Adequately controlled thyroid function, with no symptoms of thyroid dysfunction
14.Able to swallow and retain oral medications and without gastrointestinal illnesses that would preclude absorption of cediranib or olaparib
15.Postmenopausal or evidence of non-childbearing status for women of childbearing potential as confirmed by a negative urine or serum pregnancy test within 7 days prior to start of IPs

Exclusion Criteria

1.Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
2.Previous enrollment in the present study.
3.Exposure to any IP during the last 4 weeks prior to enrollment.
4.Previous treatment with PARP inhibitor. For this study, BSI-201 (iniparib) is not considered as PARPi
5.Recent cancer-directed therapies: Radiotherapy (RT) within 4 weeks, chemotherapy or other systemic anti-cancer therapy within 4 weeks, or prior anti-angiogenic treatment (e.g., bevacizumab) within 6 weeks prior to starting treatment
6.Cancer antigen-125 (CA-125) only disease without RECIST 1.1 measurable disease
7.Major surgical procedure within 2 weeks prior to starting treatment; patients must have recovered from any effects of any major surgery and surgical wound should have healed prior to starting treatment
8.Clinically significant signs and/or symptoms of bowel obstruction within 3 months prior to starting treatment
9.History of intra-abdominal abscess within 3 months prior to starting treatment
10.History of GI perforation. Patients with a history of abdominal fistula will be considered eligible if the fistula was surgically repaired, there has been no evidence of fistula for at least 6 months prior to starting treatment, and patient is deemed to be at low risk of recurrent fistula
11.Other malignancy within the last 5 years
12.Persisting ≥Grade 2 CTCAE toxicity (except alopecia and Grade 2 peripheral neuropathy) from previous anti-cancer treatment(s)
13.Central nervous system metastases
14.Patients with any of the following: History of myocardial infarction within 6 months prior to starting treatment; Unstable angina; Resting electrocardiogram (ECG) with clinically significant abnormal findings; New York Heart Association functional classification of III or IV
15.Left ventricular ejection fraction (LVEF) < lower limit of normal (LLN) per institutional guidelines, or <55%, if threshold for normal not otherwise specified by institutional guidelines, for patients with the following risk factors: Prior treatment with anthracyclines; Prior treatment with trastuzumab; Prior central thoracic RT, including exposure of heart to therapeutic doses of ionizing RT; History of myocardial infarction within 6-12 months prior to start of IPs; Prior history of other significant impaired cardiac function
16.History of stroke or transient ischemic attack within 6 months
17.Uncontrolled intercurrent illness
18.Patients with myelodysplastic syndrome (MDS)/ treatment-related acute myeloid leukemia (t-AML) or with features suggestive of MDS/AML
19.No prior allogenic bone marrow transplant or double umbilical cord blood transplantation
20.Known active human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C infection on antiviral treatment
21.Concomitant use of known strong or moderate CYP3A inhibitors
22.Concomitant use of known strong or moderate CYP3A inducers

No locations available

Arms	Assigned Interventions
Experimental: combination of cediranib and olaparib Open label	Drug: cediranib and olaparib Cediranib tablets oral dose 30 mg once daily; Olaparib(Lynparza) tablet 200 mg twice daily Dose reduction for both products is allowed Other Name: Olaparib: also known as Lynparza

Documents available

CSR synopsis
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

[email protected]

Contact Backup

Tsveta Milenkova